Literature DB >> 22030695

Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment.

M Li1, Z Chen, W Deng, Z He, Q Wang, L Jiang, X Ma, Y Wang, S E Chua, C Cheung, G M McAlonan, P C Sham, D A Collier, Q Gong, T Li.   

Abstract

BACKGROUND: Brain structure appears to alter after antipsychotic administration, but it is unknown whether these alterations are associated with improvement of psychopathology in patients with schizophrenia. In this study, the authors explore this relationship.
METHOD: Altogether, 66 first-episode, drug-naive patients with schizophrenia and 23 well-matched healthy controls underwent brain magnetic resonance imaging scans at baseline. All 23 healthy controls and 42 of the patients were rescanned after 6 weeks follow-up. The patients received regular antipsychotic treatment during the 6-week period and their psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS) at baseline and 6 weeks. The difference in PANSS scores between baseline and 6 weeks was expressed as a ratio of the scores at baseline - 'PANSS reduction ratio'. A modified tensor-based morphometry procedure was applied to analyse longitudinal images. Correlations between regional volume changes, PANSS reduction ratio and antipsychotic drug dosages were explored.
RESULTS: Compared with healthy controls, there was a significant increase in grey-matter volume of the right putamen in patients after 6 weeks treatment. This volume change was positively correlated with a positive PANSS reduction score but not related to drug dosages.
CONCLUSIONS: Putaminal volume increased after 6 weeks antipsychotic treatment in first-episode schizophrenia. The increased volume was closely correlated with improved psychopathology, suggesting the putamen might be a biomarker to predict the treatment response in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22030695     DOI: 10.1017/S0033291711002157

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  25 in total

1.  First- and second-generation antipsychotic drug treatment and subcortical brain morphology in schizophrenia.

Authors:  Kjetil N Jørgensen; Ragnar Nesvåg; Sindre Gunleiksrud; Andrea Raballo; Erik G Jönsson; Ingrid Agartz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-11-07       Impact factor: 5.270

Review 2.  Neuroimaging markers of antipsychotic treatment response in schizophrenia: An overview of magnetic resonance imaging studies.

Authors:  Goda Tarcijonas; Deepak K Sarpal
Journal:  Neurobiol Dis       Date:  2018-06-25       Impact factor: 5.996

3.  Subcortical Brain Volume Abnormalities in Individuals With an At-risk Mental State.

Authors:  Daiki Sasabayashi; Yoichiro Takayanagi; Tsutomu Takahashi; Naoyuki Katagiri; Atsushi Sakuma; Chika Obara; Masahiro Katsura; Naohiro Okada; Shinsuke Koike; Hidenori Yamasue; Mihoko Nakamura; Atsushi Furuichi; Mikio Kido; Yumiko Nishikawa; Kyo Noguchi; Kazunori Matsumoto; Masafumi Mizuno; Kiyoto Kasai; Michio Suzuki
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

4.  Functional brain networks in never-treated and treated long-term Ill schizophrenia patients.

Authors:  Li Yao; Fei Li; Jieke Liu; Wei Liao; Xiaojing Li; Mingli Li; Yajing Meng; Sugai Liang; Chengcheng Zhang; Xiao Yang; Qiang Wang; Xiaohong Ma; Wanjun Guo; John A Sweeney; Qiyong Gong; Su Lui; Wei Deng; Tao Li
Journal:  Neuropsychopharmacology       Date:  2019-06-04       Impact factor: 7.853

5.  Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA.

Authors:  Miran Kenk; Thiviya Selvanathan; Naren Rao; Ivonne Suridjan; Pablo Rusjan; Gary Remington; Jeffrey H Meyer; Alan A Wilson; Sylvain Houle; Romina Mizrahi
Journal:  Schizophr Bull       Date:  2014-11-09       Impact factor: 9.306

6.  Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication.

Authors:  Nathan L Hutcheson; David G Clark; Mark S Bolding; David M White; Adrienne C Lahti
Journal:  Psychiatry Res       Date:  2013-10-22       Impact factor: 3.222

7.  Larger putamen size in antipsychotic-naïve individuals with schizotypal personality disorder.

Authors:  Eran Chemerinski; William Byne; Jeanine C Kolaitis; Cathryn F Glanton; Emily L Canfield; Randall E Newmark; M Mehmet Haznedar; Vladan Novakovic; King-Wai Chu; Larry J Siever; Erin A Hazlett
Journal:  Schizophr Res       Date:  2012-11-24       Impact factor: 4.939

8.  A multi-scanner study of subcortical brain volume abnormalities in schizophrenia.

Authors:  Theo G M van Erp; Douglas N Greve; Jerod Rasmussen; Jessica Turner; Vince D Calhoun; Sarah Young; Bryon Mueller; Gregory G Brown; Gregory McCarthy; Gary H Glover; Kelvin O Lim; Juan R Bustillo; Aysenil Belger; Sarah McEwen; James Voyvodic; Daniel H Mathalon; David Keator; Adrian Preda; Dana Nguyen; Judith M Ford; Steven G Potkin
Journal:  Psychiatry Res       Date:  2014-02-28       Impact factor: 3.222

9.  Increased subcortical region volume induced by electroconvulsive therapy in patients with schizophrenia.

Authors:  Xiaoxiao Shan; Haisan Zhang; Zhao Dong; Jindong Chen; Feng Liu; Jingping Zhao; Hongxing Zhang; Wenbin Guo
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-07-17       Impact factor: 5.270

10.  Increased regional homogeneity modulated by metacognitive training predicts therapeutic efficacy in patients with schizophrenia.

Authors:  Xiaoxiao Shan; Rongyuan Liao; Yangpan Ou; Pan Pan; Yudan Ding; Feng Liu; Jindong Chen; Jingping Zhao; Wenbin Guo; Yiqun He
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-03-25       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.